Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK1 | P23458 | 20/20 | 0.90 |
| ▸ | TYK2 | P29597 | 4/20 | 0.71 |
| ▸ | JAK3 | P52333 | 4/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.71 |
| ▸ | JAK2 | O60674 | 5/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25236969 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL29460603 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL29460538 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25285276 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25282290 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25288520 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25285275 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25288519 | 1.00 | JAK1 (0.90) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25237999 | 0.96 | JAK1 (0.82) | JAK1TYK2JAK3CYP3A4KCNH2 | |
| SCHEMBL25279148 | 0.96 | JAK1 (0.82) | JAK1TYK2JAK3CYP3A4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240383898-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | YIYOU BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-11-21 | — | — | US | claimed |
| US-20240383898-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | YIYOU BIOTECH (SHANGHAI) CO., LTD. (CN) | 2024-11-21 | — | — | US | disclosed |
| CN-114149428-A | Pyridine-fused ring compound and preparation method, intermediate, composition and application thereof | 中国药科大学 | 2022-03-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240383898-A1 | PYRIDO RING COMPOUND, PREPARATION METHOD THEREFOR, INTERMEDIATE, COMPOSITION, AND APPLICATION | JAK1, WEE1, JAK2 | JAK1 1/4885TYK2 7/4885JAK3 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.